Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
PCVX 
Vaxcyte Inc (PCVX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/19/2025: PCVX (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $92
1 Year Target Price $92
| 9 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 59.99% | Avg. Invested days 47 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 12/19/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 6.08B USD | Price to earnings Ratio - | 1Y Target Price 92 |
Price to earnings Ratio - | 1Y Target Price 92 | ||
Volume (30-day avg) 10 | Beta 1.28 | 52 Weeks Range 27.66 - 93.77 | Updated Date 12/21/2025 |
52 Weeks Range 27.66 - 93.77 | Updated Date 12/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.85 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -15.07% | Return on Equity (TTM) -20.83% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 4449791728 | Price to Sales(TTM) - |
Enterprise Value 4449791728 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -14.43 | Shares Outstanding 130906263 | Shares Floating 117926907 |
Shares Outstanding 130906263 | Shares Floating 117926907 | ||
Percent Insiders 0.64 | Percent Institutions 110.49 |
Upturn AI SWOT
Vaxcyte Inc
Company Overview
History and Background
Vaxcyte, Inc. was founded in 2013 with a mission to develop innovative vaccines against infectious diseases. It emerged from Alkami, a company focused on synthetic biology. A significant milestone was the company's IPO in July 2020, which provided capital for its pipeline development. Vaxcyte has been focused on leveraging its proprietary Xpress CFu2122 platform to create differentiated vaccines.
Core Business Areas
- Vaccine Development: Vaxcyte's core business revolves around the discovery, development, and commercialization of novel vaccines. Their approach utilizes synthetic biology and advanced computational tools to design vaccines with improved efficacy and broader coverage against challenging pathogens.
Leadership and Structure
Vaxcyte is led by a management team with extensive experience in biotechnology and vaccine development. The company operates as a clinical-stage biopharmaceutical company, focusing on its research and development pipeline.
Top Products and Market Share
Key Offerings
- VXX-031 (RSV Vaccine): VXX-031 is a differentiated vaccine candidate designed to prevent respiratory syncytial virus (RSV) infection. It aims to offer broad protection against both RSV-A and RSV-B strains. Competitors include Pfizer (Abrysvo), GSK (Arexvy), and Sanofi/AstraZeneca. Market share data is not yet applicable as the product is in clinical development.
- VXX-014 (Shingles Vaccine): VXX-014 is a next-generation vaccine candidate targeting varicella-zoster virus (VZV), the virus that causes shingles. It aims to provide enhanced efficacy and durability compared to existing options. Competitors include Shingrix (GSK) and Zostavax (Merck). Market share data is not yet applicable as the product is in clinical development.
- VXX-021 (Pneumococcal Vaccine): VXX-021 is a novel pneumococcal conjugate vaccine designed to provide broader serotype coverage against Streptococcus pneumoniae, a leading cause of pneumonia and other serious infections. Competitors include Prevnar 13/20 (Pfizer) and Vaxzevria (AstraZeneca). Market share data is not yet applicable as the product is in clinical development.
Market Dynamics
Industry Overview
The vaccine market is a significant and growing sector within the pharmaceutical industry, driven by an aging global population, increasing awareness of infectious diseases, and the development of new vaccine technologies. The market is characterized by high R&D costs, lengthy development timelines, and stringent regulatory requirements, but also by substantial unmet medical needs and potential for significant returns.
Positioning
Vaxcyte positions itself as an innovator in vaccine development, leveraging its proprietary Xpress CFu2122 platform to create differentiated vaccines that address limitations of existing therapies. Its focus on synthetic biology and computational design aims to yield vaccines with improved efficacy, broader coverage, and potentially better safety profiles. The company's competitive advantage lies in its platform technology and its pipeline of candidates targeting significant infectious diseases.
Total Addressable Market (TAM)
The total addressable market for vaccines is vast, encompassing preventative healthcare for a wide range of infectious diseases. For example, the global RSV vaccine market is projected to reach tens of billions of dollars. Vaxcyte is positioned to capture a portion of this TAM by developing advanced vaccine candidates for diseases with significant market potential, such as RSV, shingles, and pneumococcal disease.
Upturn SWOT Analysis
Strengths
- Proprietary Xpress CFu2122 platform for vaccine design and manufacturing.
- Pipeline of differentiated vaccine candidates targeting significant unmet medical needs.
- Experienced management team with a strong track record in biotechnology.
- Strong scientific foundation and emphasis on innovation.
Weaknesses
- Clinical-stage company with no approved products, leading to significant R&D expenses and no current revenue generation from product sales.
- Reliance on external funding for continued development and operations.
- Potential for long development timelines and the inherent risks associated with clinical trials.
Opportunities
- Growing global demand for effective vaccines against infectious diseases.
- Advancements in biotechnology and synthetic biology enabling novel vaccine approaches.
- Partnership and collaboration opportunities with larger pharmaceutical companies.
- Potential for expanding vaccine indications and market reach.
Threats
- Failure of pipeline candidates in clinical trials.
- Competition from established pharmaceutical companies with extensive resources and existing market share.
- Regulatory hurdles and delays in the approval process.
- Changes in healthcare policy and reimbursement landscapes.
- Inability to secure sufficient funding to advance pipeline.
Competitors and Market Share
Key Competitors
- Pfizer Inc. (PFE)
- GlaxoSmithKline plc (GSK)
- Merck & Co., Inc. (MRK)
- Sanofi S.A. (SNY)
Competitive Landscape
Vaxcyte faces intense competition from established pharmaceutical giants with significant market share, R&D budgets, and commercial infrastructure. While Vaxcyte's platform offers a novel approach, its lack of approved products means it is currently a smaller player. Its advantage lies in its potential to develop superior vaccines with broader coverage or improved efficacy, which could disrupt the market for existing therapies.
Growth Trajectory and Initiatives
Historical Growth: Vaxcyte's historical growth has been characterized by its transition from a private entity to a publicly traded company, significant investment in its proprietary platform, and the advancement of its vaccine candidates through preclinical and early-stage clinical trials. Its growth is measured by pipeline progression and scientific milestones rather than traditional revenue metrics.
Future Projections: Future projections for Vaxcyte are heavily dependent on the successful progression of its clinical pipeline, particularly for its lead candidates targeting RSV, shingles, and pneumococcal disease. Analyst estimates will focus on the potential market penetration of these candidates and the timing of potential commercialization. Success in late-stage clinical trials and regulatory approvals would be key drivers of significant future growth.
Recent Initiatives: Recent initiatives likely include: progression of VXX-031 (RSV) into later-stage clinical trials, advancement of VXX-014 (shingles) and VXX-021 (pneumococcal) through their respective development pathways, potential collaborations or partnerships to accelerate development and commercialization, and ongoing efforts to optimize its Xpress CFu2122 platform.
Summary
Vaxcyte Inc. is a promising clinical-stage biopharmaceutical company focused on developing innovative vaccines using its proprietary Xpress CFu2122 platform. The company has a strong scientific foundation and a pipeline targeting significant unmet medical needs in infectious diseases like RSV, shingles, and pneumococcal disease. However, it faces substantial risks inherent in drug development, including clinical trial failures and intense competition from established players. Securing adequate funding and demonstrating clinical efficacy are critical for its future success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Vaxcyte, Inc. SEC Filings (10-K, 10-Q)
- Company Investor Relations Websites
- Financial Data Aggregators (e.g., Yahoo Finance, Bloomberg)
- Industry Research Reports
Disclaimers:
This JSON output is for informational purposes only and does not constitute financial advice. The data presented is based on publicly available information and may not be exhaustive or entirely up-to-date. Market share figures are estimates and can fluctuate. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Vaxcyte Inc
Exchange NASDAQ | Headquaters San Carlos, CA, United States | ||
IPO Launch date 2020-06-12 | Co-Founder, CEO & Director Mr. Grant E. Pickering M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 414 | Website https://vaxcyte.com |
Full time employees 414 | Website https://vaxcyte.com | ||
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; and VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.